MedTrace Logo

To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra

NCT01501435 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2017-01-02

No results posted yet for this study

Summary

To investigate the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra

Conditions

  • Healthy

Interventions

DRUG

CJ-30039

single dose

DRUG

fenofibric acid

single dose

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • Min-su Park, MD PhD · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-04-30
Completion
2012-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01501435 on ClinicalTrials.gov